EVOTEC SE INH O.N.EE

EVOTEC SE INH O.N.

8.260EURD
0.0000.00%
As of today at 08:09 GMT
EUR
No trades
See on Supercharts

EVT fundamentals

Key facts

Market capitalization‪1.51 B‬EUR
Basic EPS (TTM)−0.97EUR
Founded1998
Employees (FY)‪5 K‬
CEOChristian Wojczewski
Websiteevotec.com
About

Evotec SE engages in the discovery and development of new drugs for pharmaceutical and biotechnology companies. It operates through the following segments: EVT Execute and EVT Innovate. The EVT Execute segment provides stand-alone or integrated drug discovery solutions for collaborators targets and programmers on a typical fee-for-service basis or through a variety of commercial structures, which may include performance-based components, such as milestones and royalties. The EVT Innovate develops drug discovery projects, assets and platforms, both internally or through academic collaborations. The company was founded by Manfred Eigen, Karsten Henco, Ulrich Aldag, Freimut Leidenberger, Heinrich Maria Schulte, Rudolf Rigler, and Charles Weissmann on December 8, 1993 and is headquartered in Hamburg, Germany.

Ownership
‪‪177.51 M‬‬
Free Float shares
‪‪131.54 M‬‬ (74.1%)
Closely held shares
‪‪45.97 M‬‬ (25.9%)
Free Float shares
‪‪131.54 M‬‬ (74.1%)
Closely held shares
‪‪45.97 M‬‬ (25.9%)
Capital structure
Market cap
‪‪1.51 B‬‬
Debt
‪‪470.05 M‬‬
Cash & equivalents
‪‪303.27 M‬‬
Enterprise value
‪‪1.68 B‬‬

Valuation

Fundamental metrics to determine fair value of the stock

Summary
‪‪1.51 B‬‬
Price to earning ratio (P/E)
Price to sales ratio (P/S)
1.89x
Market Cap
Net income
Revenue
Price to earning ratio (P/E)
Price to sales ratio (P/S)
1.89x
Valuation ratios
Q3 '23
Q4 '23
Q1 '24
Q2 '24
Q3 '24
‪0.00‬
‪0.90‬
‪1.80‬
‪2.70‬
‪3.60‬
P/S

Growth and Profitability

Company’s recent performance and margins

Performance
‪−56%‬
‪−44%‬
‪−32%‬
‪−20%‬
‪−8%‬
Q3 '23
Q4 '23
Q1 '24
Q2 '24
Q3 '24
‪‪−100.00 M‬‬
‪0.00‬
‪‪100.00 M‬‬
‪‪200.00 M‬‬
‪‪300.00 M‬‬
Revenue
Net income
Net margin %
Revenue to profit conversion
Revenue
COGS
Gross profit
Op expenses
Op income
Non-Op income/ expenses
Taxes & Other
Net income
‪‪−70.00 M‬‬
‪0.00‬
‪‪70.00 M‬‬
‪‪140.00 M‬‬
‪‪210.00 M‬‬
Revenue
COGS
Gross profit
Expenses & adjustments
Net income
‪‪−70.00 M‬‬
‪0.00‬
‪‪70.00 M‬‬
‪‪140.00 M‬‬
‪‪210.00 M‬‬

Revenue breakdown

Revenue streams and regions a business earns money from

By source/business
Period: 2023
EVT Execute
EVT Innovate
By country
Period: 2023
United States
Rest of the World
United Kingdom
Switzerland
Germany
France

Estimates

Revenue and Earnings forecasts and estimates accuracy

Revenue
Q4 '23
Q1 '24
Q2 '24
Q3 '24
Q4 '24
‪0.00‬
‪‪60.00 M‬‬
‪‪120.00 M‬‬
‪‪180.00 M‬‬
‪‪240.00 M‬‬
Actual
Estimate
Earnings
Next:Mar 27, 2025
Q4 '23
Q1 '24
Q2 '24
Q3 '24
Q4 '24
‪−0.60‬
‪−0.40‬
‪−0.20‬
‪0.00‬
‪0.20‬
Actual
Estimate

Dividends

Dividend yield, history and sustainability

EVT does not pay dividends
The company has not previously paid dividends and at the moment there is no information about whether it is going to pay them in the future

Financial health

Financial position and solvency of the company

Debt level and coverage
Q3 '23
Q4 '23
Q1 '24
Q2 '24
Q3 '24
‪‪−210.00 M‬‬
‪0.00‬
‪‪210.00 M‬‬
‪‪420.00 M‬‬
‪‪630.00 M‬‬
Debt
Free cash flow
Cash & equivalents
Financial position analysis
Short term
Long term
‪0.00‬
‪‪350.00 M‬‬
‪‪700.00 M‬‬
‪‪1.05 B‬‬
‪‪1.40 B‬‬
Assets
Liabilities